S

Sanofi

Global pharma company; vaccines and R&D

Group Lead - Scientific Writing

Full-TimeDeadline 11/30/26
No salary listed
Expert
Hyderabad, Telangana, India
In Person
Content & WritingTechnical Writing

About the job

Requirements
  • At least 10 years of experience in content creation for the pharmaceutical or healthcare industry, or academia.
  • Strong ability to manage a multi-layered team of at least 10 members.
  • Ability to influence and negotiate.
  • Stakeholder management, communication skills, and people management.
  • Ability to work independently and within a team environment.
  • Proficiency in multiple therapeutic areas or domains under one global business unit, as applicable.
  • Scientific communications or writing, medical communications or writing, publication planning, and/or project management, as applicable.
  • Advanced degree in life sciences, pharmacy, a similar discipline, or a medical degree.
  • Excellent spoken and written English.
Responsibilities
  • Provide functional and operational direction across therapeutic areas and processes to create synergies and optimize deliveries through multi-layered teams, with a cost-savings objective.
  • Lead teams of writers, including junior writers through team leads, content support teams, and operations staff such as project specialists through project managers.
  • Coach and develop team leads, expert and senior writers, and similar roles on content, methods, and processes.
  • Maintain effective relationships with medical-scientific stakeholders within allocated therapeutic areas or global business units and products, with the objective of developing education and communication content.
  • Ensure new technologies are leveraged.
  • Act as a strategic thought partner to at least one therapeutic area within an assigned global business unit.
  • Develop and maintain expertise in at least one therapeutic area and in key industry trends and developments.
  • Provide input for publication and communication plans, publication and medical education materials, and other strategic deliverables, and ensure delivery to agreed timelines and quality standards.
  • Lead and support development of tools, technology, and processes to continuously improve quality and productivity.
  • Support project delivery by the medical writing group, ensuring appropriate resourcing, quality, timeliness, efficiency, and high technical standards for scientific documents and clinical or medical reports.
  • Enhance quality by ensuring high scientific standards for output produced by the scientific writing group.
  • Ensure adherence to compliance procedures and internal and operational risk controls in accordance with applicable regulatory standards.
  • Manage end-to-end processes through PromoMats, iEnvision (formerly Datavision), and Matrix.
  • Ensure publication and medical education materials are delivered to agreed timelines and quality standards.
  • Maintain effective relationships with medical-scientific stakeholders to develop education and communication content as required.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...